Professor Jin-ling TANG (唐金陵教授)
MD (PKU), MSc (LSHTM), PhD (Lond.), FACE, FFPH (UK)

Associate Director (Mainland Development), JC School of Public Health and Primary Care                                                                                                            
Head, Division of Epidemiology

Director, The Hong Kong Branch of the Chinese Cochrane Centre

Professor 

 

Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

depid_jinling_tang150.jpg 
Biography 

Professor Jin Ling TANG joined the Department of Community and Family Medicine of the Chinese University of Hong Kong in 1995. He qualified as a public health doctor in Peking University Medical School (formerly Beijing Medical University) and was later awarded, by the Chinese Ministry of Education, the Sino-British Friendship Scholarship for reading for a PhD in the United Kingdom. He obtained his Master of Science degree in epidemiology in London School of Hygiene and Tropical Medicine and PhD in the University of London, and received post-doctoral training in the University of Oxford. He was awarded in 2002 Cheung Kong Scholars Professor of Peking University by the Ministry of Education and Li Ka Shing Foundation.

Professor Tang is a trained epidemiologist and has a major interest in evidence-based healthcare, traditional Chinese medicine, systematic reviews and critical appraisal of medical evidence. He heads the Hong Kong Cochrane Branch of the Cochrane Collaboration and is the Chairman of the Asia Pacific Network for Evidence-Based Medicine. He is con-currently appointed the Chairman of Peking University National 211 Project Committee for Evidence-Based Medicine and heads Peking University Centre for Evidence-Based Medicine and Clinical Research. He is a member of the Chinese National Committee for Health Risk Management and also a guest professor of the Chinese Academy of Chinese Medical Sciences and Sun Yat-Sen University and consultant scientist of the People’s Hospital of Guang Dong Province.

Professor Tang serves as an editorial board member of medical journals including British Medical Journal-Chinese Edition and Journal of Evidence-Based Medicine. He proposed the efficacy driven approach to research and development in traditional Chinese medicine to the Legislative Council of the Hong Kong Government and was invited to speak on the topic at the World Economic Forum 2001 China Business Summit. He co-authored Evidence-Based Decision Making in Healthcare with Sir Muir Gray of the University of Oxford and was the co-editor of the Chinese version of the BMJ Clinical Evidence. His major research interests include systematic reviews and meta-analysis, evidence-based medicine and evidence-based healthcare, clinical evaluation of traditional Chinese Medicine, primary prevention of cardiovascular disease, tobacco smoking and health, clinical trials, evaluation of diagnosis, and epidemiology. He has supervised ten PhD students and over twenty MPH/MSc students.

Teaching Modules 
- Evidence-based medicine and evidence-based healthcare
- Sources of evidence and critical appraisal
- Meta-analysis, systematic reviews, publication bias
- Design of clinical trials and observational studies
- Primary prevention of cardiovascular disease
- Causes, causation and causal models
- Interaction and dose-response relationship
- Bias and its prevention in clinical studies
- Epidemiology and statistics in EBM
Research Interests 
  • Systematic reviews and meta-analysis
  • Evidence-based medicine & evidence-based healthcare
  • Clinical research in efficacy of traditional Chinese medicine
  • Primary prevention of cardiovascular disease
  • Clinical research on prognosis, diagnosis and efficacy
学习与工作经历 
北京大学医学部（原北京医学院）医学学士，伦敦大学硕士、博士，牛津大学博士后。现任香港中文 大学公共卫生及基层医疗学院流行病学教授、署理院长、流行病学部主任。曾任北京大学长江学者、特聘教授、博士生导师，以及北京大学医学部13个国家重点学 科组成的“十一五”“211工程循证医学学科群”牵头人。获前国家教委中英友好奖学金公派赴英国攻读博士学位，获国家教育部和李嘉诚基金会颁发的长江学者 奖。
主要学术兼职 
2004年参与创建亚太循证医学联盟（Asia Pacific EBM Network, APEBMN），并任该联盟主席至今；2011年出任亚太公共卫生联盟（Asia-Pacific Academic Consortium for Public Health, APACPH）副主席；现兼任香港考科蓝中心（Hong Kong Cochrane Branch）主任、北京大学循证医学中心主任；复旦大学循证医学中心客座教授、英国公共卫生学会资深会员、中华预防医学会流行病学分会常委、中华预防医 学会健康风险评估与控制专业委员会常委；英国医学杂志中文版、中华医学杂志英文版、健康管理等杂志编委；北京大学、复旦大学、中山大学客座教授，中国中医 科学院特聘客座研究员。
主要研究领域 
主要研究领域涉及循证医学、医学决策信息、临床试验、系统综述、中医药临床研究、心血管病初级 预防等方面的工作。系统分析并论证了中国心血管病初级预防的整体危险策略；为香港立法会提出“以疗效为先导的中医药研究与发展纲要”，应邀在“世界经济论 坛”2001年北京商务高峰会做该主题的演讲，并为英国医学杂专辑和柳叶刀杂志做有关评述；与牛津大学卫生科学院前院长、英国卫生信息总监Muir Gray爵士合著《循证医疗卫生决策》，主译国际权威医学证据资源《临床证据》；与牛津大学循证医学中心前主任Paul Glasziou教授主编教育部“十一五”规划教材《循证医学基础》，译Muir Gray爵士的《聪明的病人》。
Selected Publications 
1. Tang JL. Randomized Controlled Trials. [随机对照试验] In: Li Li-Ming: Epidemiology (6th Edition). Beijing: People’s Medial Press, 2007. View PDF
2. Tang JL. Data analysis and interpretation in clinical epidemiological studies. [临床流行病学数据的分析与結果解释] In: Li Li-Ming: Clinical Epidemiology. Beijing: People’s Medial Press, 2011. View PDF
3. Tang JL. Foreword for Evidence-Based M. [循证医学是一道亮丽风景线] In: Tang JL, Paul Glasziou: Foundation of Evidence-based Medicine. Beijing: Peking University Medical Press, 2010. View PDF
4. Tang JL. The collection, arrangement and propagation of research evidence. [研究证据的收集、整理和传播] In: Tang JL, Paul Glasziou: Foundation of Evidence-based Medicine. Beijing: Peking University Medical Press, 2010. View PDF
5. Tang JL, Wang WZ. Analysis of the evidence and rationale behind the strategies for pharmacological prevention of cardiovascular diseases. [循证决策实例：心血管病药物预防策略背后的证据和逻辑] In: Tang JL, Paul Glasziou: Foundation of Evidence-based Medicine. Beijing: Peking University Medical Press, 2010. View PDF
6. Tang JL, Wang S (Translators主译). BMJ Clinical Evidence. [英国医学杂志《临床证据》中文版] Beijing: Peking University Medical Press, 2007.  
7. Muir Gray, Tang JL. Evidence-Based Decision Making in Healthcare. [循证医学循证医疗卫生决策] Beijing: Peking University Medical Press 2004.  
8. Tang JL. Doctors need also learn how to comfort patients. [医的魔术，医者的心] Health Management 2011; 2(5):86-89. View PDF
9. Yang ZY, Mao C, Tang JL. Comments on: Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2012; 366(8): 767.  
10. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012; 23(6): 1518-25.  
11. Tang JL, Wang S. Defining and providing essential evidence for practice. [确定和提供医学实践需要的证据] Clinical Evidence Nov. 17, 2008. View PDF
12. Tang JL. The continuing barriers to research in China. [中国学术研究的障碍] CMAJ 2010; 182(5): 424-5. View PDF
13. Tang JL. Evidenced pyramid and new solutions on evidence-based practice. [ 证据金字塔与循证实践新思路] Chin J Epidemiol 2011; 32 (12): 1193-98. View PDF
14. Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. [检测Meta分析中的发表偏倚:误导的漏斗图] J Clin Epidemiol 2000; 53 (5): 477-84. View PDF
15. Tang JL. Weighting bias in meta-analysis of binary outcomes. [Meta分析中的权重偏倚] J Clin Epidemiol 2000; 53(11): 1130-6. View PDF
16. Tang JL. Selection bias in meta-analyses of gene-disease associations [perspective]. [疾病基因研究Meta分析中的选择偏倚] PLoS Med 2005; 2 (12): e409. View PDF
17. Tang JL. Research priorities in traditional Chinese medicine. [试论以疗效为先导的中医药研究策略] BMJ (Chinese Edition) 2006; 04: 222-226. View PDF
18. Tang JL. Research priorities in traditional Chinese medicine. [试论以疗效为先导的中医药研究策略] BMJ 2006; 333(7564): 391-4. View PDF
19. Tang JL. Traditional Chinese medicine. [中医药及其临床疗效研究] Lancet (Chinese Edition) 2008; 01: 94-97. View PDF
20. Tang JL, Liu BY, Ma KW. Traditional Chinese medicine. [中医药及其临床疗效研究] Lancet 2008; 372(9654): 1938-40. pdf-icon.png
21. Tang JL. Some reflections on the evaluation of clinical effectiveness of Chinese medicine. [关于中医临床效果研究的若干思考] Chin J Integr Med 2010; 16(5): 390-1. View PDF
22. Tang JL, Zhan SY, Ernst E. Review of randomized controlled trials of traditional Chinese medicine. [中医药随机对照试验的方法学质量评价] BMJ 1999; 319(7203): 160-1. View PDF
23. Wang WZ, Tang JL. Medical screening: to be or not to be? [医学筛查：做，还是不做?] Chin Med J (Engl) 2010; 123(14): 1948-51. View PDF
24. Tang JL, Hu YH. Drugs for preventing cardiovascular disease in China. [Editorial] [药物预防心血管病：治疗阈值应因资源多寡而定] BMJ 2005; 330(7492): 610-1. View PDF
25. Tang JL, Armitage J, Lancaster T, et al. A systematic review of dietary intervention trials on cholesterol lowering in free-living individuals. [饮食干预降低血胆固醇效果的系统综述] BMJ 1998; 316(7139): 1213-20. View PDF
26. Tang JL, Wang WZ, An JG, et al. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city. [我国居民对降压药物治疗的支付意愿] Int J Epidemiol 2010; 39 (1): 244-54. View PDF
27. Wang WZ, Tang JL, Hu YH, et al. Gap between evidence and physicians’knowledge and practice regarding hypertension and its drug treatment: a survey in a Chinese city. [医生高血压及其药物治疗的知识和实践与证据之间的差距] Chin Med J (Engl) 2011; 124(8): 1235-41. View PDF
28. Tang JL, Dickinson JA, Liu JL. Coronary risk assessment methods and cholesterol lowering. Lancet 1999; 353: 1095-96.  
29. Wu HM, Tang JL, Lin XP, Lau J, Leung PC, Woo J, Li YP.  Acupuncture for Stroke Rehabilitation. The Cochrane Library, 2007.  
30. Tang JL, Morris JK, Wald NJ, et al. Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts. [香烟焦油含量与死亡率关系的前瞻性研究] BMJ 1995;3 11(7019): 530-3. View PDF
31. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. [戒烟治疗措施效果的Meta分析] Arch Intern Med 1995; 155(18): 1933-41. 25. View PDF
32. Tang JL, Law M, Wald NJ. How effective is nicotine replacement therapy in helping people to stop smoking. [尼古丁替代治疗戒烟效果的系统综述] BMJ 1994;308(6920): 21-6. View PDF
33. Lai TC, Tang JL. A systematic review protocol of effectiveness of motivational interview on smoking cessation. The Cochrane Library, 2008.  
34. Tang JL, Muir J, et al. Health profiles of current and former smokers and lifelong abstainers. J Roy Coll Phys Lond 1997; 31(3): 304-09.  
35. Bista MB, Banerjee MK, Shin SH, Tandam JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358: 791-5.  
36. Yuan JQ, Zhang RJ, Yang ZY, Lee J, Liu YL, Tian JH, Qin XW, Ren ZJ, Ding H, Chen Q, Mao C and Tang JL. Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis. Eur Urol. 2013 Jan 31. (In press) View PDF
37. Liu JL, Tang JL. Assessing prevention interventions by "number needed to treat" JAMA 2000; 284: 303-4.  
 
[ Back ]